Thyrotoxic crisis induced by amiodarone therapy

Author(s):  
Marianna Bystrianska ◽  
Adrian Bystriansky
2011 ◽  
Vol 33 (6) ◽  
pp. 750-756 ◽  
Author(s):  
Ryosuke Araki ◽  
Eiji Yukawa ◽  
Mihoko N Nakashima ◽  
Hiromitsu Fukuchi ◽  
Hitoshi Sasaki ◽  
...  

2013 ◽  
Vol 5 (Suppl 2) ◽  
pp. A52.1-A52
Author(s):  
R Morgan ◽  
S Best ◽  
C Connor ◽  
P Johnson ◽  
J Madarang
Keyword(s):  

2007 ◽  
Vol 41 (7-8) ◽  
pp. 1310-1314 ◽  
Author(s):  
Leanne Stafford

Objective: To describe a case of a hypersensitivity reaction to oral amiodarone in a patient with a previous reaction to an iodinated radiocontrast agent. Case Summary: A 55-year-old man experienced facial urticaria after intraarterial injection of iohexol, an iodinated radiocontrast agent, during coronary angiography, which was successfully treated with intravenous hydrocortisone and promethazine. The procedure revealed significant triple vessel disease, and the patient subsequently underwent coronary artery bypass grafting in October 2006. Postoperatively, the patient experienced 2 episodes of fast atrial fibrillation, the first of which was treated successfully with intravenous amiodarone. The second episode resulted in the commencement of therapy with oral amiodarone 400 mg 3 times daily. Within one hour after the first dose, the patient experienced tip swelling and tingling, which was again treated with intravenous promethazine. Amiodarone was stopped; the patient remained in sinus rhythm and was discharged without further incident. Discussion: Amiodarone is a class III antiarrhythmic agent frequently used in the management of atrial fibrillation after cardiac surgery. The approved product information lists known hypersensitivity to iodine as a contraindication to its administration, but no other cases of amiodarone hypersensitivity in a patient with a previous reaction to an iodinated radiocontrast agent have been published, Conversely, it has been suggested that the drug may be safely used in such patients. The Naranjo probability scale supported a probable adverse reaction of hypersensitivity associated with amiodarone therapy in this patient. Conclusions: Prescribers should exercise caution in the administration of amiodarone to patients with a true, documented history of hypersensitivity to an iodinated compound.


2000 ◽  
Vol 43 (3) ◽  
pp. 95-101
Author(s):  
Stanislav Mičuda ◽  
Martin Hodač ◽  
Petr Pařízek ◽  
Miloslav Pleskot ◽  
Luděk Šišpera ◽  
...  

The present work was designed to determine whether the individual differences in pharmacokinetics and pharmacodynamics of amiodarone and its N-desethyl metabolite are related to cytochrome CYP3A metabolizer status. Methods: 12 cardiac patients with inducible ventricular tachyarrhythmias during the baseline electrophysiologic study were enrolled in this study. Urinary 24-hour excretion of 6β-hydroxycortisol (6β-OHC and the ratio of 6β-hydroxycortisol to urinary free cortisol (6β-OHC/UFC) were measured before the first amiodarone administration. Trough plasma concentrations of amiodarone and N-desethylamiodarone (N-DEA) were measured after 79 ± 11 days (2nd period) and after 182 ± 25 days (3rd period). Electrophysiologic effects of amiodarone therapy were established with serial electrophysiologic studies in 9 of these patients at the baseline and after 79 ± 11 days (during the second period). Results: Both the 6β-OHC excretion and 6β-OHC/UFC ratio varied approximately 6-fold between the patients. We found significant inverse correlation between the 6β-OHC excretion and the trough plasma concentrations of amiodarone at the time of the 3rd period (rs = -0.58, p < 0.05). Similarly, there was correlation between the 24-hour urinary 6β-OHC excretion and trough plasma concentrations of amiodarone during the 3rd period (rs = -0.64, p < 0.025). We were unable to detect any association between CYP3A activity and amiodarone pharmacodynamics. Conclusion: This study points toward important information value of CYP3A metabolizer status in the context of therapeutic drug monitoring of amiodarone.


2013 ◽  
Vol 5 (1) ◽  
pp. 21-24 ◽  
Author(s):  
Avraham Ishay ◽  
Julia Carmeli ◽  
Ehud Rozner ◽  
Rafael Luboshitzky

ABSTRACT Amiodarone-induced thyrotoxicosis is often poorly tolerated owing to underlying cardiac disease, and frequently resistant to medical therapy. We describe a 48-year-old patient with severe cardiac disease who developed amiodarone-associated thyrotoxicosis, refractory to standard medical therapy. Due to the unremitting thyrotoxicosis, a total thyroidectomy was performed without complications resulting in rapid correction of the thyrotoxicosis and enabling resumption of amiodarone therapy. Despite the concerns inherent to severe cardiac disease, total thyroidectomy can be performed safely in patients with resistant amiodarone-induced thyrotoxicosis. We believe that surgery should be considered early in the treatment planning. How to cite this article Ishay A, Carmeli J, Rozner E, Luboshitzky R. Refractory Amiodarone-induced Thyrotoxicosis: The Surgical Option. World J Endoc Surg 2013;5(1):21-24.


2014 ◽  
Vol 04 (03) ◽  
pp. 109-118 ◽  
Author(s):  
Padmavathi Mali ◽  
Michele M. Henry Salzman ◽  
Humberto J. Vidaillet ◽  
Shereif H. Rezkalla

2015 ◽  
Vol 8 (2) ◽  
pp. 71-78
Author(s):  
Sergey Yur'yevich Astakhov ◽  
Natal'ya Viktorovna Tkachenko ◽  
Sanasar Surikovich Papanyan

Cordarone keratopathy corresponds to medically induced corneal changes developing with time in a majority of patients against the background of systemic cordarone (amiodarone) therapy. This condition does threaten by substantial visual function decrease and does not demand medication withdrawal. Similar intraepithelial corneal inclusions may be found in treatment by several other medications, as well as in Fabry disease. This is to be reminded when considering differential diagnosis.


Sign in / Sign up

Export Citation Format

Share Document